EXEL
Exelixis Inc
NASDAQ: EXEL · HEALTHCARE · BIOTECHNOLOGY
$44.46
-0.51% today
Updated 2026-04-30
Market cap
$11.35B
P/E ratio
16.08
P/S ratio
4.89x
EPS (TTM)
$2.78
Dividend yield
—
52W range
$34 – $50
Volume
2.7M
Exelixis Inc (EXEL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
33.70%
Operating margin
39.40%
ROE
35.50%
ROA
19.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $98.67M | $-101.49M | 99.17% | -128.46% | -102.86% |
| 2007 | $113.47M | $-86.38M | 99.82% | -138.40% | -76.13% |
| 2008 | $117.86M | $-162.85M | 100.00% | -152.14% | -138.18% |
| 2009 | $151.76M | $-135.22M | 100.00% | -80.33% | -89.10% |
| 2010 | $185.04M | $-92.33M | 100.00% | -49.39% | -49.90% |
| 2011 | $289.64M | $75.70M | 100.00% | 30.91% | 26.14% |
| 2012 | $47.45M | $-147.65M | 100.00% | -258.03% | -311.16% |
| 2013 | $31.34M | $-244.76M | 96.43% | -640.54% | -781.03% |
| 2014 | $25.11M | $-268.54M | 91.86% | -893.86% | -1,069.42% |
| 2015 | $37.17M | $-169.74M | 89.52% | -326.65% | -456.63% |
| 2016 | $191.45M | $-70.22M | 96.58% | -14.69% | -36.68% |
| 2017 | $452.48M | $154.23M | 96.67% | 36.67% | 34.09% |
| 2018 | $853.83M | $690.07M | 96.91% | 51.40% | 80.82% |
| 2019 | $967.77M | $321.01M | 96.58% | 38.18% | 33.17% |
| 2020 | $987.54M | $111.78M | 96.33% | 11.14% | 11.32% |
| 2021 | $1.43B | $231.06M | 96.32% | 19.98% | 16.10% |
| 2022 | $1.61B | $182.28M | 96.41% | 12.51% | 11.31% |
| 2023 | $1.83B | $207.76M | 96.04% | 9.34% | 11.35% |
| 2024 | $2.17B | $521.27M | 96.49% | 27.88% | 24.04% |
| 2025 | $2.32B | $782.57M | 96.39% | 37.59% | 33.73% |